Gerresheimer (GXI) Q2 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 TU earnings summary
30 Sep, 2026Executive summary
Q2 2026 adjusted EBITDA rose over 50% quarter-on-quarter to EUR 102 million, with margin at 17.6%, driven by operational recovery and transformation initiatives.
Q2 2026 revenue was EUR 578 million, up EUR 55 million sequentially from Q1, though down year-on-year.
All business segments contributed positively to the quarter-on-quarter improvement.
Major divestitures (Centor and Primary Packaging Plastics) are progressing, with Centor closing expected in October 2026 and PPP in H1 2027.
Transformation program targets EUR 50–70 million EBITDA improvement by end of 2027/2028, focusing on operational excellence and cost efficiencies.
Financial highlights
Q2 2026 revenue was EUR 578 million, down from EUR 614 million year-on-year, but up EUR 55 million from Q1.
Adjusted EBITDA for Q2 was EUR 102 million, down year-on-year but up EUR 35 million from Q1.
Free cash flow before M&A was negative EUR 92 million, mainly due to working capital movements and reduced reverse factoring.
Net CapEx reduced to EUR 38 million, 35% below prior year, with 60% of spend on growth projects.
Net financial debt stands slightly above EUR 2 billion, with liquidity at EUR 249 million.
Outlook and guidance
Full-year 2026 guidance confirmed: revenue in the lower half of EUR 2.3–2.4 billion, adjusted EBITDA margin 17–18%, and negative free cash flow before M&A of EUR 50–100 million.
Stronger second half expected, with Q4 traditionally the strongest quarter due to seasonality.
Transformation initiatives expected to deliver full EBITDA improvement run rate from 2028.
GLP-1 franchise targets for 2027 remain in place, supported by strong contracts.
Management targets better H2 performance versus H1.
Latest events from Gerresheimer
- Transformation, compliance, and portfolio focus drive financial recovery and future growth.GXI
AGM 2026 - Cash discipline, asset sales, and transformation drove best Q1 free cash flow since 2019.GXI
Q1 2026 - FY25 revenue up 17% to EUR 2.3bn, but margin and cash flow declined amid restructuring.GXI
Q4 2025 - Sustainable growth fueled by innovation, digitalization, and global capacity expansion.GXI
Investor Presentation - 2024 guidance cut as vial demand lags and US plant flooding impacts results.GXI
Q3 2024 TU - Q2 2024 showed resilient results, strong Plastics & Devices, and a major pharma acquisition.GXI
Q2 2024 - Bormioli Pharma deal lifts revenue, but net income falls and leverage rises to 3.97x.GXI
Q1 2025 - Strong Q4 growth and Bormioli integration drive robust 2025 outlook and margin expansion.GXI
Q4 2024 - 2025 outlook and dividend cut as weak H1 demand prompts lower growth and margin guidance.GXI
Q2 2025 TU